Subbiah will report to Serge Stankovic, M.D., M.S.P.H., Acadia's president and be responsible for corporate medical affairs including medical strategy, scientific communications, and medical science liaison activities.
Subbiah is a neurologist with over 20 years of experience in the pharmaceutical industry and global health sector.
She has led the development and execution of medical and clinical research strategies in various therapeutic areas, including neurology, psychiatry, opioid addiction, pain, oncology, diabetes, urology, inflammation, respiratory, and infectious diseases.
Subbiah was most recently chief medical officer for Indivior Inc., with responsibility for pharmacovigilance and medical affairs globally.
She was also the company spokesperson at policy discussions including testifying at the presidential Commission on Combating Drug Addiction and Opioid Crisis and the hearing by the House Committee on Energy and Commerce on the opioid crisis.
During her previous tenure of over 15 years at Pfizer, Inc., she held various leadership roles in global medical affairs and led Pfizer's Global Access program to improve healthcare access for low-income populations in the developing world through approaches that were commercially viable and sustainable.
Acadia is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. Acadia has developed and commercialised the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Acadia also has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, schizophrenia, major depressive disorder, and Rett syndrome.
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval
INOVIO prices USD25m public offering
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
Seegene launches STAgora infectious disease analytics platform
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Immuno Cure and PharmaJet collaborate for novel HIV therapeutic DNA vaccine advancement
Oxurion signs LOI to acquire majority stake in preclinical microbiology CRO
bioMérieux acquires Day Zero Diagnostics assets to expand rapid sequencing diagnostics
EDX Medical and Spire Healthcare sign strategic diagnostic partnership agreement
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
Ondine's Steriwave proven effective against deadly Mucor fungus
Mycovia Pharmaceuticals reports first participant enrolled in Phase 2 cryptococcal meningitis study
bioMérieux launches rapid PCR test for equine respiratory diseases
Ondine Biomedical joins CAN Health Network to advance Steriwave adoption in Canada
Seegene presrnts CURECA conceptual video at ESCMID Global 2025